Products for Research Use Only
RegisterLogin

Quilseconazole

CAT: 0804-HY-109040-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-109040-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Quilseconazole (VT-1129) is an orally active, highly selective fungal cytochrome P450 enzyme Cyp51 inhibitor that can cross the blood-brain barrier. Quilseconazole prevents the synthesis of ergosterol, an important component of the fungal cell membrane, by inhibiting Cyp51. Quilseconazole has minimal effects on human CYP enzymes. Quilseconazole has antifungal activity and can be used in the study of cryptococcal meningitis and other diseases[1][2][3].
CAS Number
1340593-70-5
Product Name Alternative
VT-1129
UNSPSC
12352005
Target
Cytochrome P450; Fungal
Type
Reference compound
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Infection; Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/quilseconazole.html
Purity
98.61
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O[C@@](CN1C=NN=N1)(C(C=CC(F)=C2)=C2F)C(F)(C3=CC=C(C4=CC=C(OC(F)(F)F)C=C4)C=N3)F
Molecular Formula
C22H14F7N5O2
Molecular Weight
513.37
References & Citations
[1]Lockhart SR, et al. The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii. Antimicrob Agents Chemother. 2016 Mar 25;60 (4) :2528-31.|[2]Wiederhold NP, et al. In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy. Antimicrob Agents Chemother. 2018 Oct 24;62 (11) :e01315-18.|[3]Warrilow AG, et al. The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme. Antimicrob Agents Chemother. 2016 Jul 22;60 (8) :4530-8.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CYP51

Alternative Products

CatalogName
BA1727-5.1Quilseconazole
A19305-50Quilseconazole 50mg
A19305-25Quilseconazole 25mg
A19305-100Quilseconazole 100mg
A19305-10Quilseconazole 10mg
A19305-5Quilseconazole 5mg
A19305-1Quilseconazole 1mg
MBS5802183Quilseconazole Formic acid (1340593-70-5 Free base)

Popular Products